Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intratumoral Flu Vaccine + Pembrolizumab in Early pMMR CRC
NCT05909423Phase 2Not yet recruiting
- Sponsor
- Zealand University Hospital
- Start
- Sep 2023
- Primary completion
- Sep 2025
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of influenza vaccine in colorectal cancer (CRC), sponsored by Zealand University Hospital. Primary endpoint: Pathological response. Planned start Sep 2023; status: not yet recruiting.
02
Drugs
influenza vaccine
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05909423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05909423.